Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease.

Saad A., Dietz AB., Herrmann SMS., Hickson LJ., Glockner JF., McKusick MA.

Clinical Trial with a reported sample of 14 on Systemic / IV, published in J Am Soc Nephrol (2017) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Am Soc Nephrol (2017)
Country
United States
Reported sample size
14
Source database
PubMed
PMID
28461553
DOI
10.1681/ASN.2017020151

Abstract (original English)

Atherosclerotic renovascular disease (RVD) reduces renal blood flow (RBF) and GFR and accelerates poststenotic kidney (STK) tissue injury. Preclinical studies indicate that mesenchymal stem cells (MSCs) can stimulate angiogenesis and modify immune function in experimental RVD. We assessed the safety and efficacy of adding intra-arterial autologous adipose-derived MSCs into STK to standardized medical treatment in human subjects without revascularization. The intervention group ( n =14) received a single infusion of MSC (1.0 × 10 5 or 2.5 × 10 5 cells/kg; n =7 each) plus standardized medical treatment; the medical treatment only group ( n =14) included subjects matched for age, kidney function, and stenosis severity. We measured cortical and medullary volumes, perfusion, and RBF using multidetector computed tomography. We assessed tissue oxygenation by blood oxygen level-dependent MRI and GFR by iothalamate clearance. MSC infusions were well tolerated. Three months after infusion, cortical perfusion and RBF rose in the STK (151.8-185.5 ml/min, P =0.01); contralateral kidney RBF increased (212.7-271.8 ml/min, P =0.01); and STK renal hypoxia (percentage of the whole kidney with R2*>30/s) decreased (12.1% [interquartile range, 3.3%-17.8%] to 6.8% [interquartile range, 1.8%-12.9%], P =0.04). No changes in RBF occurred in medical treatment only subjects. Single-kidney GFR remained st

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAtherosclerosisFemaleGlomerular Filtration RateHumansHypoxiaInfusions, Intra-ArterialKidney

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research